THERACYS- bacillus calmette-guerin substrain connaught live antigen injection, powder, lyophilized, for solution
Sanofi Pasteur Inc.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use TheraCys safely and effectively. See full prescribing information for TheraCys.
TheraCys®, BCG Live (Intravesical) Initial U.S. Approval: 1990 WARNING - RISK OF BCG TRANSMISSION AND INFECTIONSee full prescribing information for complete boxed warning.
RECENT MAJOR CHANGES
INDICATIONS AND USAGETheraCys is indicated for intravesical treatment and prophylaxis of urinary bladder carcinoma in situ (CIS) and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). (1) Limitation of Use: TheraCys is not recommended for DOSAGE AND ADMINISTRATIONDOSAGE FORMS AND STRENGTHS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most common adverse reactions observed with TheraCys treatment at a rate > 10% were transient dysuria, urinary frequency and urgency, malaise, hematuria, fever, chills, cystitis, and mild nausea. Symptoms of bladder irritability were reported in approximately 50% of patients receiving TheraCys, typically beginning 4-6 hours after instillation and lasting 24-72 hours. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Pharmacovigilance Department, Sanofi Pasteur Inc. at 1-800-822-2463 (1-800-VACCINE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONSBladder capacity: There is an increased risk of bladder contracture when instilling TheraCys in patients with small bladder capacity. (8.6) See 17 for PATIENT COUNSELING INFORMATION. Revised: 11/2015 |
TheraCys is indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).
Limitation of Use: TheraCys is not recommended for
For intravesical instillation only.
Do not inject intravenously, subcutaneously, intradermally or intramuscularly.
Begin intravesical treatment of the urinary bladder a minimum of 14 days after biopsy or transurethral resection. Treatment consists of induction and maintenance therapy. For the induction therapy, administer one dose (81mg) of TheraCys each week for 6 consecutive weeks. For the maintenance therapy, administer one dose at 3, 6, 12, 18, and 24 months following the initial dose.
To avoid cross-contamination, do not prepare parenteral drugs in areas where TheraCys has been prepared. Handle and dispose of all equipment, supplies and receptacles in contact with TheraCys as biohazardous waste (or material). Wear gloves and eye protection and take precautions to avoid contact of BCG with broken skin. In addition, if the preparation cannot be performed in a biocontainment hood, wear a mask and gown.
Use aseptic techniques.
Do not use any reconstituted product that exhibits flocculation or clumping that cannot be dispersed with gentle shaking.
Do not expose reconstituted product to sunlight, direct or indirect.
Keep exposure to artificial light to a minimum.
Insert a urethral catheter into the bladder under aseptic conditions, drain the bladder, instill 50 mL suspension of TheraCys slowly by gravity, and then withdraw the catheter.
Have the patient retain the suspension for as long as possible for up to two hours. During the first 15 minutes following instillation, the patient should lie prone. Thereafter, allow the patient to be in an upright position.
At the end of 2 hours, have the patient void in a seated position for safety reasons.
Instruct the patient to increase fluid intake in order to flush the bladder in the hours following BCG treatment.
Immediately place unused product, packaging, and all equipment and materials used for instillation of the product (e.g., syringes, catheters) in a container for biohazardous materials, and dispose of them according to local requirements applicable to biohazardous materials.
Properly dispose of voided urine during the 6 hr period following TheraCys instillation with an equal volume of 5% hypochlorite solution. [See Patient Counseling Information (17)]
One dose of TheraCys consists of one 81 mg vial of freeze-dried BCG reconstituted and diluted in 50 mL sterile, preservative-free saline.
Known systemic hypersensitivity reaction to any component of TheraCys [See Warnings and Precautions (5.6) and Description (11)] or after a previous administration of TheraCys or after a previous administration of TheraCys or a medicinal product containing the same substances is a contraindication to the administration of TheraCys.
Because of the risk of disseminated BCG infection, immunosuppressed persons with congenital or acquired immune deficiencies, whether due to concurrent disease (e.g., AIDS, leukemia, lymphoma), cancer therapy (e.g., cytotoxic drugs, radiation), or immunosuppressive therapy (e.g., corticosteroids) should not receive TheraCys. [See Drug Interactions (7.1)]
Do not use TheraCys in patients with current symptoms or a previous history of systemic BCG reaction. [See Warnings and Precautions (5.1)]
A minimum of 14 days must elapse before TheraCys is administered following biopsy, TUR, or traumatic catheterization.
A systemic BCG reaction may occur subsequent to exposure to TheraCys. This reaction is a systemic granulomatous illness that may be defined as the presence of any of the following signs, if no other etiologies for such signs are detectable: fever ≥39.5°C (≥103.1°F) for ≥12 hours; fever ≥38.5°C (≥101.3°F) for ≥48 hours; pneumonitis; hepatitis; other organ dysfunction outside of the genitourinary tract with granulomatous inflammation on biopsy; or the classical signs of sepsis, including circulatory collapse, acute respiratory distress, and disseminated intravascular coagulation.
Because it is usually difficult to isolate BCG organisms from affected organs, the extent such a reaction is caused by an infectious process versus an inflammatory hypersensitivity reaction often is unclear. If TheraCys is administered within two weeks of either biopsy, TUR or traumatic bladder catheterization (associated with hematuria), a systemic BCG reaction is much more likely to occur. Death has been reported with the use of TheraCys in association with systemic BCG reaction in post-marketing experience.
BCG dissemination may occur when administered by the intravesical route.
BCG infections of aneurysms and prosthetic devices (including arterial grafts, cardiac devices, and artificial joints) have been reported. The risk of these ectopic BCG infections has not been determined. The benefits of TheraCys therapy must be carefully weighed against the possibility of an ectopic BCG infection in patients with pre-existing arterial aneurysms or prosthetic devices of any kind.
To help prevent serious infections, avoid trauma and/or introduction of contaminants to the urinary tract. Wait a minimum of 14 days after traumatic catheterization before administering TheraCys. Resume TheraCys treatment according to the original schedule.
BCG may persist in the urinary tract for several months after BCG instillations and delayed manifestations of disseminated BCG infection may develop months or years after BCG therapy. Patients who receive immunosuppressive therapy after BCG instillation may be at higher risk of disseminated BCG infection.
Monitor patients for the presence of symptoms and signs of toxicity after each intravesical treatment. If a patient develops persistent fever or experiences an acute febrile illness consistent with BCG infection, permanently discontinue BCG instillations, evaluate and treat the patient immediately for BCG infection, and seek an infectious diseases consultation. As standard therapy for BCG infection, promptly initiate treatment with 2 or more antimycobacterial agents while conducting diagnostic evaluation, including cultures. Do not use single antibiotic therapy. Negative cultures do not rule out infection.
Some male genitourinary tract infections (orchitis/epididymitis) have been refractory to multiple drug antituberculous therapy and have required orchiectomy.
TheraCys is not sensitive to pyrazinamide.
If a bacterial urinary tract infection (UTI) occurs during the course of TheraCys treatment, withhold TheraCys instillation until complete resolution of the bacterial UTI.
Do not use antimycobacterial drugs (e.g., isoniazid) prophylactically to prevent the local, irritative side effects of TheraCys. They may affect the effectiveness of TheraCys and there are no data to suggest that the acute, local urinary tract symptoms common with intravesical BCG are due to mycobacterial infection.
Because TheraCys contains live mycobacteria, prepare, handle and dispose of TheraCys, and all equipment, supplies and receptacles in contact with TheraCys, as biohazardous waste (or material). Use aseptic techniques, wear gloves and eye protection, and take precautions to avoid contact of TheraCys with broken skin. Avoid needle stick injuries during the handling and mixing of TheraCys.
BCG infections have been reported in health care workers preparing BCG for administration. Nosocomial infections have been reported in immunosuppressed patients receiving parenteral drugs that were prepared in areas in which BCG was prepared.
The most common adverse reactions observed with TheraCys treatment at a rate > 10% were transient dysuria, urinary frequency and urgency, malaise, hematuria, fever, chills, cystitis, and mild nausea.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a medicinal product cannot be directly compared to rates in the clinical trials of another medicinal product and may not reflect the rates observed in practice.
Administration of TheraCys causes an inflammatory response in the bladder, thus requiring careful patient monitoring. Symptoms of bladder irritability are reported in approximately 50% of patients receiving TheraCys and typically begin 4-6 hours after instillation and last 24-72 hours. The irritative reactions usually are seen following the third instillation and tend to increase in severity after each administration. There is no evidence that dose reduction or antituberculous drug therapy can prevent or lessen the irritative symptoms of TheraCys.
In a clinical trial conducted in the United States, patients with stage Ta or T1 papillary tumor with 2 or more recurrences within the last 12 months, with carcinoma in situ (CIS), or with both of these conditions, were randomized to receive treatment with intravesical TheraCys or doxorubicin. Prior therapy with either BCG or doxorubicin was not allowed. Patients with muscle-invasive cancers or incomplete resection of papillary tumors were not eligible. One-hundred and twelve patients received TheraCys in 6 weekly instillations, followed by single instillations at 3, 6, 12, 18, and 24 months after enrollment, and were included in safety analyses. In the control group, 119 patients received doxorubicin in 5 weekly treatments, followed by 11 monthly treatments. Safety information was collected prior to each treatment dose.
Table 1 shows the frequency of adverse reactions observed in this trial. Local irritative symptoms were more common with TheraCys than with doxorubicin; however, grade ≥ 3 irritative toxicity was similar, occurring in approximately 2-7% of patients. Systemic symptoms (fever, chills, malaise, anorexia) were also more common with TheraCys. Overall, grade ≥ 3 toxicities were seen in 26 patients (23%) treated with TheraCys and 25 patients (21%) treated with doxorubicin. TheraCys treatment was discontinued in twelve patients due to toxicity.
Study Arm | ||||
---|---|---|---|---|
System/Organ Class | TheraCys (N=112) | Doxorubicin (N=119) | ||
Adverse reaction | All Grades % | Grade ≥3 % | All Grades % | Grade ≥3 % |
Infections and Infestations | ||||
Cystitis | 29.5 | 0 | 19.3 | 0.8 |
Urinary tract infection | 17.9 | 0 | 17.6 | 0 |
Pulmonary infection | 2.7 | 0 | 4.2 | 0.8 |
Systemic infection | 2.7 | 1.8 | 0.8 | 0 |
Infection | 0.9 | 0.9 | 0.8 | 0 |
Blood and Lymphatic System Disorders | ||||
Anemia | 20.5 | 0 | 24.4 | 0 |
Leukopenia | 5.4 | 0 | 5.9 | 0 |
Coagulopathy/ Thrombocytopenia | 0.9 | 0 | 0.8 | 0 |
Metabolism and Nutrition Disorders | ||||
Anorexia | 10.7 | 0 | 5.0 | 0 |
Nervous System Disorders | ||||
Headache | 1.8 | 0 | 3.4 | 0 |
Dizziness | 0.9 | 0 | 0.8 | 0 |
Cardiac Disorders | ||||
Cardiac (unclassified) | 2.7 | 0 | 3.4 | 0.8 |
Gastrointestinal Disorders | ||||
Nausea/Vomiting | 16.1 | 0 | 8.4 | 0.8 |
Diarrhea | 6.3 | 0 | 1.7 | 0 |
Abdominal pain | 2.7 | 0 | 2.5 | 0 |
Constipation | 0.9 | 0 | 0.8 | 0 |
Hepatobiliary Disorders | ||||
Liver involvement | 2.7 | 0 | 0.8 | 0 |
Skin and Subcutaneous Tissue Disorders | ||||
Skin rash | 1.8 | 0 | 2.5 | 0 |
Musculoskeletal, Connective Tissue, and Bone Disorders | ||||
Arthralgia/Myalgia/ Arthritis | 7.1 | 0.9 | 4.2 | 0 |
Flank pain | 0.9 | 0 | 0.8 | 0 |
Renal and Urinary Disorders | ||||
Dysuria | 51.8 | 3.6 | 40.3 | 5.9 |
Urinary frequency | 40.2 | 1.8 | 28.6 | 4.2 |
Hematuria | 39.3 | 7.1 | 27.7 | 6.7 |
Urinary urgency | 17.9 | 0.9 | 11.8 | 2.5 |
Renal toxicity (NOS) | 9.8 | 1.8 | 9.2 | 0.8 |
Urinary incontinence | 6.3 | 0 | 0.8 | 0.8 |
Bladder cramps/pain | 6.3 | 0 | 5.0 | 1.7 |
Contracted bladder | 5.4 | 0.9 | 5.0 | 0.8 |
Tissue in urine | 0.9 | 0 | 1.7 | 0 |
Ureteral obstruction | 0.9 | 0.9 | 0 | 0 |
Reproductive System and Breast Disorders | ||||
Genital pain | 9.8 | 0 | 13.4 | 1.7 |
General Disorders and Administration Site Conditions | ||||
Malaise | 40.2 | 1.8 | 14.3 | 0 |
Fever (>38°C) | 38.4 | 2.7 | 9.2 | 0 |
Chills | 33.9 | 2.7 | 5.9 | 0 |
Fatigue | 0.9 | 0 | 0 | 0 |
The following additional adverse reactions have been identified during post-approval use of TheraCys. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Infections and Infestations
BCG Infection: BCG is capable of dissemination when administered by the intravesical route. Serious infections, including sepsis with associated mortality, have been reported. BCG infections have also been reported in eye, lung, liver, bone, bone marrow, kidney, regional lymph nodes, peritoneum, genitourinary tract (orchitis/epididymitis), and prostate (e.g., Granulomatous prostatitis). BCG infection of aneurysms and prosthetic devices (including arterial grafts, cardiac devices and artificial joints) has also been reported.
Latent BCG Infection: BCG may persist in the urinary tract for several months after BCG instillations and delayed manifestations of disseminated BCG infection may develop months or years after BCG therapy. Patients who receive immunosuppressive therapy after BCG instillation may be at higher risk of disseminated BCG infection.
Joint symptoms (arthritis, arthralgia), ocular symptoms (including conjunctivitis, uveitis, iritis, keratitis, granulomatous choreoretinitis), urinary symptoms (including urethritis), skin rash, alone or in combination (Reiter's syndrome), have been reported following administration of TheraCys. For the reports of Reiter's syndrome, the risk seems to be more elevated among patients who are positive for HLA-B27.
Renal abscess
Treatments using immunosuppressants, myelosuppressants, or radiation interfere with the development of the immune response to TheraCys and increase the risk of disseminated BCG infection.
Carefully consider TheraCys treatment decisions in patients with a condition that may require future mandatory immunosuppression (e.g., awaiting an organ transplant, myasthenia gravis).
Antimicrobial therapy for other infections may interfere with the effectiveness of TheraCys.
Intravesical treatment with TheraCys may induce a positive response to a tuberculin skin test [tuberculin purified protein derivative (PPD)], which may complicate future interpretations of skin test reactions to PPD when used to diagnose suspected mycobacterial infections. If a patient's reactivity to PPD needs to be determined, the Tuberculin Skin Test should be conducted before administration of TheraCys.
Pregnancy Category C
Animal reproduction studies have not been conducted with TheraCys. It is also not known whether TheraCys can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. TheraCys should not be given to a pregnant woman unless clearly needed. Women should be advised not to become pregnant while on therapy.
It is not known whether TheraCys can be excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from TheraCys in nursing infants, it is advisable to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness of TheraCys for the treatment of superficial bladder cancer in pediatric patients have not been established.
In clinical studies with TheraCys, analyses evaluating the differences in safety and efficacy between study subjects 65 years of age and older versus younger subjects were not performed. No other data are available about the potential impact of age on the safety and efficacy of TheraCys.
Overdosage occurs if more than one vial of TheraCys is administered per instillation. If overdosage occurs, closely monitor the patient for signs of active local or systemic infection [See Warnings and Precautions (5.2)].
TheraCys, BCG Live (Intravesical) is a freeze-dried preparation made from the Connaught strain of Bacillus Calmette and Guérin, which is an attenuated strain of Mycobacterium bovis.
The BCG organisms in the product are grown on media containing potatoes, glycerine, asparagine, citric acid, potassium phosphate, magnesium sulfate, ferric ammonium citrate, calcium chloride, copper sulfate, and zinc sulfate. Monosodium glutamate is added to the BCG organisms prior to freeze-drying.
Each vial of TheraCys contains 81 mg of freeze-dried BCG. The freeze-dried BCG does not contain any preservative.
One dose of TheraCys consists of one 81mg vial of freeze-dried BCG reconstituted and diluted in 50 mL sterile, preservative-free saline.
The BCG organisms from the vial are viable. In vitro potency is determined by an assay of live BCG organisms based on the number of colonies observed when grown on solid medium. The reconstituted product contains approximately 10.5 ± 8.7 × 108 colony-forming units (CFU) per vial.
When administered intravesically as a cancer therapy, BCG promotes a local acute inflammatory and sub-acute granulomatous reaction with macrophage and lymphocyte infiltration in the urothelium and lamina propria of the urinary bladder. The exact mechanism of action is unknown, but the anti-tumor effect appears to be T-lymphocyte-dependent.
The efficacy and safety of TheraCys were compared to doxorubicin hydrochloride in a multicenter, open-label, randomized clinical trial, in patients with carcinoma in situ (CIS) of the urinary bladder, recurrent Ta/T1 papillary tumors of any grade of the urinary bladder, or both. A total of 285 patients were randomized: 142 to treatment with doxorubicin (69 CIS and 73 non-CIS) and 143 to treatment with TheraCys (70 CIS and 73 non-CIS). All papillary tumors were completely resected prior to trial entry. TheraCys was administered intravesically weekly for 6 weeks, with additional single instillations at 3, 6, 12, 18, and 24 months following the initiation of treatment (total of 11 instillations over 2 years). The initial treatment with doxorubicin was given within 3 days of TUR, followed by 4 weekly treatments and then by 11 monthly treatments (total of 16 instillations over 1 year). Cytology and cystoscopy were obtained every 3 months for 2 years. Disease-free survival and 2-year disease-free survival were evaluated and an intent-to-treat analysis was performed.
The median age of patients treated with doxorubicin was 70 years (CIS; range 31-88 years) and 65 years (non-CIS; range 38-95 years), while the median age was 66 years (CIS; range 33-83 years) and 67 years (non-CIS; 24-95 years) in patients treated with TheraCys. The racial distribution was 89% White, 5% Black and 6% Other in the doxorubicin treatment arm and 95% White, 3% Black and 2% Other in the TheraCys treatment arm.
For patients with CIS, the complete response rate (i.e., negative biopsies and urine cytology) within 6 months of the initiation of treatment was 33% with doxorubicin and 71% with TheraCys (p < 0.001, Fisher's Exact Test). The probability of being disease-free at 2 years was 23% with doxorubicin and 51% with TheraCys (p < 0.001, Z Test). The median disease-free survival was 4.9 months for doxorubicin and 30 months for TheraCys (p < 0.001, Log Rank Test).
For patients with Ta/T1 papillary tumors only, the 2-year disease-free survival was 29% with doxorubicin and 50% with TheraCys (p = 0.008, Z Test). The median disease-free survival was 10.5 months with doxorubicin and 22.5 months with TheraCys (p = 0.001, Log Rank Test).
The results are summarized in Table 2.
Carcinoma in situ | Ta/T1 Papillary Tumors | |||
---|---|---|---|---|
Doxorubicin N = 69 | TheraCys N = 70 | Doxorubicin N = 73 | TheraCys N = 73 |
|
|
||||
Complete Response | 23 (33%) | 50 (71%) | - | - |
Median Disease-free Survival* | 4.9 Months | 30 Months | 10.5 Months | 22.5 Months |
2-Year Disease-free Survival* | 23% | 51% | 29% | 50% |
95% Confidence Interval | (15%, 35%) | (41%, 65%) | (20%, 41%) | (39%, 63%) |
Inform patients of the following:
Manufactured by:
Sanofi Pasteur Limited
Toronto Ontario Canada
Distributed by:
Sanofi Pasteur Inc.
Swiftwater PA 18370 USA
TheraCys® is a registered trademark of Sanofi, its affiliates and subsidiaries.
R9-1015 USA
THERACYS
bacillus calmette-guerin substrain connaught live antigen injection, powder, lyophilized, for solution |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
Labeler - Sanofi Pasteur Inc. (086723285) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Sanofi Pasteur Limited | 208206623 | MANUFACTURE |